Skip to main content
. 2022 Jun 20;81(10):1420–1427. doi: 10.1136/annrheumdis-2022-222435

Figure 1.

Figure 1

Flow diagram of the study population. CKD, chronic kidney disease; IST, immunosuppressive therapy; SLE, systemic lupus erythematosus.